| Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates |
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2025-05-13 22:10:34 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update |
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. |
globenewswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 |
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. |
globenewswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer |
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since November 2023. She will continue to serve as the Company's Chief Financial Officer and Treasurer. |
globenewswire.com |
2025-04-28 20:01:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript |
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief Executive Officer, Chief Financial Officer Tim Keutzer - Chief Operating Officer Conference Call Participants Gavin Clarke-Gartner - Evercore ISI Athena Chin - TD Cowen Operator Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in listen-only-mode. |
seekingalpha.com |
2025-03-27 22:31:18 |
Czytaj oryginał (ang.) |
| Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates |
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago. |
zacks.com |
2025-03-27 20:20:23 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update |
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. |
globenewswire.com |
2025-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 |
CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. |
globenewswire.com |
2025-03-18 10:00:00 |
Czytaj oryginał (ang.) |
| UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference |
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows: |
globenewswire.com |
2025-02-25 12:15:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference |
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. |
globenewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal |
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM. |
seekingalpha.com |
2025-01-19 10:00:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know |
Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-15 15:00:34 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes |
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipenem HBr Reaches Over 60% Enrollment as of December 31, 2024; Remains on Track to Complete Enrollment in 2H 2025 Cash Balance and Cash Runway Guidance Remains into mid-2026 CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (“Spero” or the “Company”) (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today provided a corporate update regarding interim changes to its leadership and Board as well as an enrollment update regarding the Phase 3 PIVOT-PO trial of Tebipenem HBr. |
globenewswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-12-16 21:36:09 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for November 15th |
FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024. |
zacks.com |
2024-11-15 07:45:20 |
Czytaj oryginał (ang.) |
| Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates |
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago. |
zacks.com |
2024-11-14 20:36:08 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update |
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. |
globenewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 |
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents |
globenewswire.com |
2024-10-16 20:05:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy |
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) |
globenewswire.com |
2024-10-02 20:30:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript |
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Officer Esther Rajavelu - CFO and Chief Business Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Gavin Clark-Gartner - Evercore ISI Ritu Baral - TD Cowen Operator Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode. |
seekingalpha.com |
2024-08-09 14:47:08 |
Czytaj oryginał (ang.) |
| Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates |
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago. |
zacks.com |
2024-08-05 22:35:56 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update |
CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. |
globenewswire.com |
2024-08-05 20:01:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 |
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline. |
globenewswire.com |
2024-07-29 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Micro-Cap Moonshots for Fearless Investors |
When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million. |
investorplace.com |
2024-07-08 19:07:22 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to each of the new employees becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-07-03 17:05:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of 116,667 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-06-03 20:05:00 |
Czytaj oryginał (ang.) |
| HC Wainwright Brokers Boost Earnings Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO) |
Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – HC Wainwright lifted their Q2 2024 EPS estimates for Spero Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.01) EPS and FY2025 earnings at ($0.87) EPS. Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $1.14. The company had revenue of $73.52 million for the quarter, compared to analyst estimates of $19.40 million. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Thursday, April 4th. Read Our Latest Research Report on SPRO Spero Therapeutics Stock Up 1.3 % SPRO opened at $1.59 on Monday. The firm has a market capitalization of $85.84 million, a P/E ratio of 3.70 and a beta of 0.62. The firm’s 50 day moving average is $1.63 and its 200-day moving average is $1.48. Spero Therapeutics has a 52-week low of $0.99 and a 52-week high of $1.94. Institutional Trading of Spero Therapeutics A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Murchinson Ltd. increased its stake in shares of Spero Therapeutics by 1.3% in the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after buying an additional 11,210 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Spero Therapeutics by 121.8% in the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after buying an additional 418,742 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after buying an additional 9,675 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Spero Therapeutics in the fourth quarter worth $1,570,000. Institutional investors own 25.60% of the company’s stock. Spero Therapeutics Company Profile (Get Free Report) Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. Read More Five stocks we like better than Spero Therapeutics How to Effectively Use the MarketBeat Ratings Screener MarketBeat Week in Review – 5/13 – 5/17 3 Ways To Invest In Coffee, Other Than Drinking It Take-Two Interactive Software Offers 2nd Chance for Investors How to Know if a Stock Pays Dividends and When They Are Paid Out Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 05:06:37 |
Czytaj oryginał (ang.) |
| Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference |
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows: |
globenewswire.com |
2024-05-16 20:05:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update |
CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial and operational results for the quarter ended March 31, 2024. |
globenewswire.com |
2024-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 |
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results. |
globenewswire.com |
2024-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 29, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 10,833 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employee, becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-05-01 20:07:00 |
Czytaj oryginał (ang.) |
| Spero Therapeutics Delivers On Game Plan To Create Shareholder Value |
Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Spero's significant undervaluation and potential path forward are highlighted in the peer comparison. |
seekingalpha.com |
2024-04-23 15:37:17 |
Czytaj oryginał (ang.) |
| Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates |
Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.55 per share a year ago. |
zacks.com |
2024-03-13 20:10:15 |
Czytaj oryginał (ang.) |